Floatz logo

HYPERICUM

Adult Solid Tumor

mixturePhase 3Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
81/ 100

Competitive context

18 Active assets in the Adult Solid Tumor cohort.

Asset / SponsorPhaseRating
Pembrolizumab
CatalYm GmbH
Phase 2BB
Docetaxel
CatalYm GmbH
Phase 3B
Nivolumab
CatalYm GmbH
Phase 2B
Crofelemer
Napo Pharmaceuticals, Inc.
Phase 3B
Durvalumab
Institut Bergonié
Phase 2B

View all 31 →

Same molecule, other indications

HYPERICUM is also rated in:

urinary system neoplasmDormant
B
Indicative ·
59 / 100
View asset →
male reproductive organ cancerDormant
B
Indicative ·
59 / 100
View asset →
thoracic cancerDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →